Nurix Therapeutics, Inc. Earnings Per Share Disclosure
| Year Ended November 30, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Numerator: | |||||||||||||||||
| Net loss | $ | (264,457) | $ | (193,569) | $ | (143,948) | |||||||||||
| Denominator: | |||||||||||||||||
Weighted-average number of shares outstanding, basic and diluted (1) | 86,666,907 | 67,120,266 | 54,337,901 | ||||||||||||||
| Net loss per share, basic and diluted | $ | (3.05) | $ | (2.88) | $ | (2.65) | |||||||||||
(1) | The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the years ended November 30, 2025, 2024 and 2023. | ||||
| Year ended November 30, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Options to purchase common stock issued and outstanding | 11,372,272 | 9,839,454 | 8,340,968 | ||||||||||||||
| Options early exercised subject to vesting | — | — | 4,909 | ||||||||||||||
| Restricted stock units issued and outstanding | 2,245,837 | 1,956,015 | 1,246,031 | ||||||||||||||
| Shares expected to be purchased under employee stock purchase plan | 185,012 | 71,541 | 203,314 | ||||||||||||||
| Total | 13,803,121 | 11,867,010 | 9,795,222 | ||||||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Jan 28, 2026 | Showing above |
| 2024 | Jan 28, 2025 | |
| 2023 | Feb 15, 2024 | |
| 2022 | Feb 9, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.